

04-01-04

1617

Attorney's Docket No.: 17170-006001
(formerly, 25835-4005)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Alan D. Snow et al. Art Unit : 1617
Serial No. : 10/077,596 Examiner : Jiang, Shaojia A.
Filed : February 15, 2002
Title : PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND
ALPHA-SYNUCLEIN DISEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF POWER OF ATTORNEY BY ASSIGNEE
AND CERTIFICATE UNDER 37 CFR §3.73(b)

Sir:


Enclosed are a Power of Attorney by Assignee, a Certificate under 37 CFR §3.73(b), and a Change of Correspondence Address Application, in connection with the above-captioned patent application. Please update your records to reflect the change of attorneys for the above-captioned patent application.

If anything further is required, please do not hesitate to contact the undersigned attorney for the assignee.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted;

Date: 3/30/04


Dale L. Rieger
Reg. No. 43,045

Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (858) 678-5099

10381253

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Services as "Express Mail" Label No. EV 399314310 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dale L. Rieger

03/18/04 THU 15:44 FAX 8588785099

FISH & RICHARDSON P.C.

035

Attorney's Docket No.: 17170-006001
(25835-4005)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Alan D. Snow et al. Art Unit : 1617
Serial No. : 10/077,596 Examiner : Jiang, Shaojia A.
Filed : February 15, 2002
Title : PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND
ALPHA-SYNUCLEIN DISEASE

POWER OF ATTORNEY BY ASSIGNEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Revoking any and all powers of attorney and authorizations of agent heretofore made in respect of the above-captioned patent application, the Assignee of the entire interest in this patent application hereby appoints the following as its attorneys, with full power of substitution and revocation, to prosecute the application and to transact all business in the Patent and Trademark Office connected therewith:

DALE L. RIEGER, 43,045; STEPHANIE SEIDMAN, Registration No. 33,779; FRED C. HERNANDEZ, Registration No. 41,832; MEGHA BHUMRALEKAR, Registration No. 44,536; and SCOTT C. HARRIS, Registration No. 32,030. Direct all telephonic inquiries to Dale L. Rieger at telephone no. (858) 678-4306.

Address all correspondence to:

Dale L. Rieger
FISH & RICHARDSON, PC
12390 El Camino Real
San Diego, California 92130

PROTEOTECH, INC.

Date: Mar 19/04By: Alan LawTitle: President / CSO

Attorney's Docket No.: 17170-006001
(25835-4005)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Alan D. Snow et al.
Serial No. : 10/077,596
Filed : February 15, 2002
Title : PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND
ALPHA-SYNUCLEIN DISEASE

Art Unit : 1617
Examiner : Jiang, Shaojia A.

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PROTEOTECH, INC., a corporation organized under the laws of Delaware, having a principal business address of 12026 115th Avenue, N.E., Kirkland, Washington 98034, U.S.A., is the Assignee of the entire right, title and interest in the above-captioned patent application by virtue of an Assignment from the inventors. A copy of the Assignment from the inventors to PROTEOTECH, INC. is attached hereto.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

PROTEOTECH, INC.

Date:

Mar 19/04

By:

Title:

Alan Snow
President / CEO